Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Want to see GB:AREC full AI Analyst Report?
Total Valuation
Arecor Therapeutics PLC has a market cap or net worth of £23.60M. The enterprise value is 20.69M .
Market Cap£23.60M
Enterprise Value20.69M
Share Statistics
Arecor Therapeutics PLC has 37,756,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,756,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arecor Therapeutics PLC’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is -66.42%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)-66.42%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee34.28K
Profits Per Employee13.28K
Employee Count50
Asset Turnover0.21
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arecor Therapeutics PLC is 35.5. Arecor Therapeutics PLC’s PEG ratio is -0.43.
PE Ratio35.5
PS Ratio17.73
PB Ratio4.71
Price to Fair Value4.71
Price to FCF-12.72
Price to Operating Cash Flow-10.30
PEG Ratio-0.43
Income Statement
In the last 12 months, Arecor Therapeutics PLC had revenue of 1.71M and earned 664.00K in profits. Earnings per share was 0.02.
Revenue1.71M
Gross Profit1.05M
Operating Income-4.67M
Pretax Income994.00K
Net Income664.00K
EBITDA-4.45M
Earnings Per Share (EPS)0.02
Cash Flow
In the last 12 months, operating cash flow was -2.29M and capital expenditures -99.00K, giving a free cash flow of -2.39M billion.
Operating Cash Flow-2.29M
Free Cash Flow-2.39M
Free Cash Flow per Share-0.06
Dividends & Yields
Arecor Therapeutics PLC pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change43.68%
50-Day Moving Average65.74
200-Day Moving Average73.20
Relative Strength Index (RSI)26.00
Average Volume (3m)40.10K
Important Dates
Arecor Therapeutics PLC upcoming earnings date is Sep 24, 2026, Before Open (Confirmed).
Last Earnings DateApr 13, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
Arecor Therapeutics PLC as a current ratio of 4.35, with Debt / Equity ratio of 1.52%
Current Ratio4.35
Quick Ratio4.35
Debt to Market Cap0.00
Net Debt to EBITDA0.65
Interest Coverage Ratio-424.18
Taxes
In the past 12 months, Arecor Therapeutics PLC has paid 62.00K in taxes.
Income Tax62.00K
Effective Tax Rate0.06
Enterprise Valuation
Arecor Therapeutics PLC EV to EBITDA ratio is -6.18, with an EV/FCF ratio of -11.51.
EV to Sales16.04
EV to EBITDA-6.18
EV to Free Cash Flow-11.51
EV to Operating Cash Flow-12.00
Balance Sheet
Arecor Therapeutics PLC has £6.13M in cash and marketable securities with £98.00K in debt, giving a net cash position of £6.03M billion.
Cash & Marketable Securities£6.13M
Total Debt£98.00K
Net Cash£6.03M
Net Cash Per Share£0.16
Tangible Book Value Per Share£0.17
Margins
Gross margin is 61.32%, with operating margin of -272.23%, and net profit margin of 38.74%.
Gross Margin61.32%
Operating Margin-272.23%
Pretax Margin57.99%
Net Profit Margin38.74%
EBITDA Margin-259.68%
EBIT Margin-272.23%
Analyst Forecast
The average price target for Arecor Therapeutics PLC is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.31%
EPS Growth Forecast21.91%